Menu Search
Equities

Shanghai Bio-heart Biological Technology Co Ltd

2185:HKG.HZ

Shanghai Bio-heart Biological Technology Co Ltd

Actions
  • Price (HKD)2.04
  • Today's Change-0.11 / -5.12%
  • Shares traded14.90k
  • 1 Year change-62.22%
  • Beta--
Data delayed at least 15 minutes, as of May 23 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Shanghai Bio-Heart Biological Technology Co Ltd is a China-based company mainly engaged in interventional instruments. The Company's main businesses are the development and production of interventional cardiovascular devices. The Company's main products include fully bioresorbable scaffolds (BRS) and renal denervation (RDN). The Company's products are mainly used to meet medical needs for the treatment of coronary, peripheral artery disease and hypertension.

  • Revenue in HKD (TTM)0.00
  • Net income in HKD-189.67m
  • Incorporated2014
  • Employees32.00
  • Location
    Shanghai Bio-heart Biological Technology Co LtdRoom 302, 3/F, Building 4No.590 Ruiqing Road, East ZhangjiangHi-Tech Park, Pudong New AreaSHANGHAI 2012201ChinaCHN
  • Phone+86 2 168798511
  • Fax+86 2 168798512
  • Websitehttp://www.bio-heart.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.